FHLT Investment Thesis & Criteria

Transcript

1. PROPRIETARY AND CONFIDENTIAL. A $200 million Health-tech SPAC Focused on disruptive companies that leverage modern technology and data-science to improve outcomes, reduce waste, and better personalize care.
2. DISCLOSURES This information is being presented pursuant Section 5 (d) of the Securities Act of 1933, as amended, and in reliance on your representation that you are a qualified institutional buyer or an institutional accredited investor as such terms are defined in the federal securities laws. These materials are not an offer to sell, and are not seeking an offer to buy, any securities of Future Health ESG Corp (the “Company,” “us,” “we” or “our”). The Company’s securities may only be sold pursuant to an effective registration statement filed with the Securities and Exchange Commission. The information provided herein is provided to you on the condition that you agree that you will hold it in strict confidence and not reproduce it or disclose it to any third party in whole or in part. By receiving this information, the recipient expressly agrees to maintain the confidentiality of the material and information herein and to use any such material and information in accordance with its compliance policies, contractual obligations and applicable law, including federal and state securities laws. The statements contained in this presentation that are not purely historical are forward looking statements. Our forward looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements. The words "anticipate," "continue,“ "could,“ "estimate,“ "expect,“ "intends,“ "may,“ "might,“ "plan, "possible,“ "potential,“ predict,“ "project,“ "should," and similar expressions may identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. The forward looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward looking statements. We undertake no obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. The past performance of our management team and their affiliates, or businesses with which they are or have been associated, is not a guarantee that we will be able to identify a suitable candidate for our initial business combination or of success with respect to any business combination we may consummate. You should not rely on the historical record or past performance of our management team or their affiliates or the businesses with which they are or have been associated as indicative of our future performance. Certain market data information in this presentation is based on management’s estimates. We obtained the industry, market and competitive position data used throughout this presentation from internal estimates and research as well as from industry publications and research, surveys and studies conducted by third parties. We believe the estimates to be accurate as of the date of this presentation. However, this information may prove to be inaccurate because of the method by which we obtained some of the data for our estimates or because this information cannot always be verified due to the limits on the availability and reliability of raw data, and the voluntary nature of the data gathering process. 2
3. Proprietary and Confidential Target Company Profile Opportunity to create shareholder value via combination with FHLT • The healthcare industry has a massive need for effective, personalized, consumer-friendly, and cost efficient care • Creating social benefit and generating above market returns Committed leadership team with owners willing to roll-over equity • An SEC-ready management team, with a vision for continued growth and desire to retain equity in the public enterprise Established leader with potential for growth via acquisition • Smart health tech with deep domain experience, robust technology, and leveraged distribution to achieve scale • Large, growing addressable market with differentiation Innovative solution to a critical, durable long term market need • Taking advantage of the shift from fee-for-service to value based healthcare with smart, precision health technology • Disrupting the healthcare and life sciences value chains Enterprise Value of $500M - $1.5B • Addressing an underserved segment of the SPAC market • Only 20 SPACs and <3% of IPO capital in this segment • Large supply of attractive combination targets 3
4. Proprietary and Confidential Digital Health is a massive, growing market 4
5. Proprietary and Confidential $410 billion wasted from lack of accurate, detailed patient data in clinical workflow ² U.S. Healthcare cost is $4.0T annually American College of Physicians calculate $528 billion wasted every year resulting in 275,000 lost lives due to under-optimized prescriptions & medication therapies ³ 5 Researchers from the Lown Institute estimate $101.2 billion wasted annually in spending due to overuse of medical tests and treatments ¹ Precision Diagnostics Opportunity $101B $528B Precision Prescribing Opportunity $410B CDS Opportunity $100B Pharma/ Biotech Opportunity Precision health technology is critical to eliminate unsustainable costs The McKinsey Global Institute estimates value up to $100 billion by applying big-data strategies to better inform clinical trial decision making 4 5
6. Proprietary and Confidential Scale-up stage health-tech companies are underserved by the current SPAC capital ecosystem Data as of July 13, 2021 Less than 3% of all SPAC capital currently searching (20 SPACs) is focused on scale-up stage healthcare technology 5 6
7. Proprietary and Confidential Operating experience in the acquired company’s industry is the biggest predictor of SPAC performance Source: Wolfe Research “We found the strongest differentiating characteristic of De-SPAC stock performance was the presence / absence of an experienced operator.” Chris Senyek Wolfe Research 6 7
8. Proprietary and Confidential Why Future Health Stands Out Operational Expertise Executive leadership and independent directors with decades of experience operating scale up and publicly traded health tech co’s. Domain Expertise Deep domain expertise in biopharma, biotech, payer, medical device, diagnostics, genomics, and precision medicine market segments. Sourcing Capability Long standing trusted relationships with executive leaders in health tech, diagnostics, pharma, clinical trials, consumer, and payer segments. Transaction Experience The team has closed dozens of private and public transactions as investors, buyers, and sellers including two SPAC IPOs and a successful de-SPAC. Value-added Advisors Delivering strong de-SPAC value add via unique expertise spanning clinical, insurance, regulatory, data science, and cloud technology. 8
9. Proprietary and Confidential References 9 1. Chalmers K, Smith P, Garber J, et al. Assessment of Overuse of Medical Tests and Treatments at US Hospitals Using Medicare Claims. JAMA Netw Open. 2021;4(4):e218075. doi:10.1001/jamanetworkopen.2021.8075 2. Berwick DM, Hackbarth AD. Eliminating Waste in US Health Care. JAMA. 2012;307(14):1513–1516. doi:10.1001/jama.2012.362 3. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018 Sep;52(9):829-837. doi: 10.1177/1060028018765159. Epub 2018 Mar 26. PMID: 29577766. 4. Jamie Cattell, Sastry Chilikuri, Michael Levy. How Big Data Can Revolutionize Pharmaceutical R&D. McKinsey Center for Government. April 1, 2013 5. “SPAC IPO Universe.” SPACInsider, 13 Feb. 2021, spacinsider.com/weekly-spac-ipo-update/. 6. YunLi626. “For SPACs, One Characteristic Seems to Determine the Investing Winners from Losers.” CNBC, CNBC, 12 July 2021, www.cnbc.com/2021/07/12/for-spacs-one-characteristic-seems-to-determine-the-investing-winners-from-losers.html.